Compare Bristol-Myers Squibb Co (BMY) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Gap Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Gap Inc trades at $20.03 (market cap $7.25B). The key difference: Bristol-Myers Squibb Co is far larger — about 16× Gap Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | GAP | |
|---|---|---|
Market Cap | $116.30B | $7.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $29.13 |
52-Week Low | $42.60 | $18.35 |
Enterprise Value | $152.24B | $10.33B |
Dividend Yield | 4.42% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Gap Inc. (GAP) trades at $19.80, up 1.75% today, with a bearish technical signal despite neutral oscillators. The stock shows strong fundamentals with a P/E of 7.86 and net income margin of 6.25%, supported by a 10-quarter positive comp trend. Recent news highlights a digital transformation with AI-led marketing and ongoing legal investigations.
The outlook is mixed; valuation metrics suggest upside to the $27 consensus target, but near-term risks include legal probes and Athleta's turnaround pace. Earnings growth and margin expansion remain key catalysts, though investor sentiment is cautious amid bearish technicals and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
